Related Experiment Videos

Using clinical trial data to tailor adjuvant treatments for individual patients

Meredith M Regan1, Richard D Gelber,

  • 1IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA. mregan@jimmy.harvard.edu

Breast (Edinburgh, Scotland)
|August 28, 2007
PubMed

Insights

Accurate pathological assessment is crucial for effective targeted therapies in early breast cancer treatment. Reliable tumor assessment ensures patients benefit from personalized treatments like trastuzumab for HER2-positive disease.

Area of Science:

  • Oncology
  • Pathology
  • Clinical Trials

Background:

  • The 2005 St. Gallen Consensus Panel emphasized target identification for early breast cancer treatment.
  • Trastuzumab's efficacy in HER2-positive breast cancer highlights the importance of targeted therapies.
  • Reliable pathological assessment is critical for the successful application of targeted treatments.

Purpose of the Study:

  • To underscore the significance of accurate pathological tumor assessment in early breast cancer.
  • To illustrate how statistical methods can individualize treatment based on clinical trial data.
  • To demonstrate the value of subgroup analyses and specific statistical tools in understanding treatment effects.

Main Methods:

  • Review of key clinical trials (BIG 1-98, HERA) and consensus recommendations.
  • Discussion of statistical methods including subgroup analyses, forest plots, and hazard rate estimation.
  • Introduction of advanced analytical tools like STEPP and recursive partitioning.

Main Results:

  • Trastuzumab's success in HER2-positive patients demonstrates the power of targeted therapy.
  • The BIG 1-98 trial emphasizes the benefit of reliable pathological assessment for targeted therapy utilization.
  • Statistical methods like forest plots and hazard rate analysis aid in understanding treatment effects across patient subgroups.

Conclusions:

  • Accurate pathological assessment is paramount for the effective use of targeted therapies in early breast cancer.
  • Statistical methodologies are essential for individualizing treatment strategies and interpreting clinical trial outcomes.
  • Advanced analytical tools enhance the understanding of treatment efficacy in specific patient subpopulations.

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...